FDA slammed after allegations it plans to use 'fresh tissue' from aborted babies to create 'mice with a human immune system'
Pro-life leaders are outraged over revelations that the federal government continues to use human tissue from abortions in medical experiments
In what is bound to be an extremely controversial decision, it has been reported that the US Food and Drug Administration and the General Services Administration, awarded a contract, on July 25, to acquire "fresh" human fetal tissue to transplant it into mice in order to give them a “human immune system".
Mad science it may be, but with Pro-Lifers this could be a ticking time bomb, especially since the FDA claims it wants the tissue for "Humanized Mice".
“Fresh human tissues are required,” said the notice, “for implantation into severely immune-compromised mice to create chimeric animals that have a human immune system.”
Advanced Bioscience Resources (ABR), a non-profit organization, was awarded the $15,900 contract which will conclude on July 25, 2019, according to GSA's federal contract database.
The fetal issue, according to the Congressional Research Service is "obtained from elective abortions”. But that may not serve to temper the vitriol sure to explode. The requirement is based on a paper published at Harvard University in 2016 that said that mice with human immune systems can only be researched through tissue from fetal material obtained from aborted babies and not conventional miscarriages.
With this contract, the FDA would be using federal tax dollars to create a demand for human body parts that must be obtained from aborted babies, reported CNS News.
The FDA is also alleged to have voiced interest in the continuation of legalized abortions at a stage in fetal development when the tissue can be retrieved from the aborted baby owing to the requirement of "fresh tissue".
“The U.S. Food and Drug Administration is committed to ensuring that its research is conducted responsibly, conforms with all legal requirements, and meets the highest ethical standards,” said the FDA statement.